Kevin Herde: Yeah, Dan, specifically, I don't think we're forcing these obligations here this year. This is really — these are actually not related to Pfizer and BioNTech. These are other customers and other regions. And this is specifically our scheduled program with them to support the finalization of their products and the launch of their programs. So I think these are very tied to what our customers expected usage is this year. And I think that you never know exactly what the uptake is going to be at the end of the quarter or at the end of the year related as this goes a little more seasonal. But as it relates to the $65 million we had this year, really tied to specific programs and our specific customer needs, and I would consider them stocking [per percent] (ph).